Kaplan Fox & Kilsheimer LLP Encourages PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to Contact the Firm Before September 22, 2026

Kaplan Fox & Kilsheimer filed a securities class action against Procept BioRobotics (PRCT) for the Class Period Feb. 28, 2024 to Feb. 25, 2026. The complaint alleges the company’s discount program caused handpiece orders to exceed procedures in every quarter, artificially inflating U.S. handpiece unit sales and revenues by pulling forward demand. While this is a legal development rather than an earnings report, it raises downside risk to PRCT’s reported revenue quality and could pressure the stock if allegations gain traction.

Analysis

This is more than headline litigation risk: it challenges the quality of PRCT’s revenue bridge. If unit sales were being pulled forward with discounting, then the market’s implicit assumption of repeatable handpiece consumption is too optimistic, and the next 1-2 quarters can show an abrupt step-down as the channel normalizes. In a consumables-led medtech model, that usually hits three things at once: revenue growth, gross margin, and the multiple investors are willing to pay for visibility.

The second-order effect is competitive. Larger platform names like ISRG, and adjacent medtech peers such as MDT or BSX, may benefit if hospital buyers reassess vendor economics and sales tactics; procurement teams tend to become more conservative after disclosure risk, which lengthens sales cycles for smaller, less-proven platforms. If the allegations are directionally right, PRCT’s share gains may have been bought rather than earned, which is bearish for long-duration expectations but potentially positive for competitors with cleaner utilization data.

Contrarian view: the market may treat this as a legal overhang when it is really a model-reset event. Settlement risk is probably manageable; the real downside is a credibility discount that can persist for multiple quarters if handpiece-to-procedure ratios fail to reconverge. Falsification is straightforward: stable procedure growth, no evidence of elevated discounting, and no gross margin compression on the next print. If management reaffirms demand normalization, the short can unwind quickly, but absent that, the path of least resistance is lower over 1-3 months.

Key Decisions for Investors

• Short PRCT on any bounce over the next 1-3 weeks; use a disciplined stop if the company shows no deterioration in procedure growth or margins on the next update. Risk/reward favors a fast de-rating if investors start haircutting forward consumables growth.
• Pair trade: long ISRG or MDT vs short PRCT for 1-3 months. Thesis is quality-of-revenue divergence; cleaner installed-base economics should attract capital if procurement scrutiny rises.
• If options liquidity is sufficient, buy PRCT put spreads expiring after the next earnings/guidance window. This expresses litigation plus model-reset risk while limiting theta if the stock already discounts part of the news.
• Do not press the short into a confirmation gap: if management discloses stable handpiece-to-procedure ratios or no discounting rebound, cover quickly. The thesis is falsified by reconvergence in the next quarter.
• Watch for channel inventory commentary and rebate/discount disclosure; any explicit mention of promotional activity easing would be the key catalyst to cover shorts.